Literature DB >> 34556525

Relationship Between 18F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies.

Keith A Josephs1, Nirubol Tosakulwong2, Stephen D Weigand2, Marina Buciuc3, Val J Lowe4, Dennis W Dickson5, Jennifer L Whitwell4.   

Abstract

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are 4-repeat (4R) tauopathies with overlapping, but also morphologically distinct, tau immunoreactive lesions that vary in count by brain region. 18F-flortaucipir PET uptake has been reported to correlate with overall tau burden, and-in 1 CBD case-to have greater affinity to threads than tangles. We determined whether 18F-flortaucipir uptake is associated with histologic lesion type in 4R tauopathies.
Methods: We performed semiquantitative regional lesion counts on pretangles/neurofibrillary tangles, threads, oligodendroglial coiled bodies, tufted astrocytes, and astrocytic plaques in 29 cases of autopsied 4R tauopathy (PSP, 16; CBD, 13). Regression models were used for statistical analyses.
Results: 18F-flortaucipir uptake marginally correlated with threads in the precentral cortex (P = 0.04) and with astrocytic lesions in the red nucleus (P = 0.05).
Conclusion: The findings do not support 18F-flortaucipir's having differential affinity to any 4R tau lesion type.
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  AV-1451; PET; corticobasal degeneration; pathology; progressive supranuclear palsy

Mesh:

Substances:

Year:  2021        PMID: 34556525      PMCID: PMC9157721          DOI: 10.2967/jnumed.121.262685

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   11.082


  18 in total

Review 1.  A systematic review of the factors affecting accuracy of SUV measurements.

Authors:  Michael C Adams; Timothy G Turkington; Joshua M Wilson; Terence Z Wong
Journal:  AJR Am J Roentgenol       Date:  2010-08       Impact factor: 3.959

Review 2.  Toward defining deep brain stimulation targets in MNI space: A subcortical atlas based on multimodal MRI, histology and structural connectivity.

Authors:  Siobhan Ewert; Philip Plettig; Ningfei Li; M Mallar Chakravarty; D Louis Collins; Todd M Herrington; Andrea A Kühn; Andreas Horn
Journal:  Neuroimage       Date:  2017-05-20       Impact factor: 6.556

3.  [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration.

Authors:  Keith A Josephs; Jennifer L Whitwell; Pawel Tacik; Joseph R Duffy; Matthew L Senjem; Nirubol Tosakulwong; Clifford R Jack; Val Lowe; Dennis W Dickson; Melissa E Murray
Journal:  Acta Neuropathol       Date:  2016-09-19       Impact factor: 17.088

4.  The relationship between histopathological features of progressive supranuclear palsy and disease duration.

Authors:  Keith A Josephs; Jayawant N Mandrekar; Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2005-12-06       Impact factor: 4.891

5.  Office of Rare Diseases neuropathologic criteria for corticobasal degeneration.

Authors:  D W Dickson; C Bergeron; S S Chin; C Duyckaerts; D Horoupian; K Ikeda; K Jellinger; P L Lantos; C F Lippa; S S Mirra; M Tabaton; J P Vonsattel; K Wakabayashi; I Litvan
Journal:  J Neuropathol Exp Neurol       Date:  2002-11       Impact factor: 3.685

6.  [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy.

Authors:  Jennifer L Whitwell; Val J Lowe; Nirubol Tosakulwong; Stephen D Weigand; Matthew L Senjem; Christopher G Schwarz; Anthony J Spychalla; Ronald C Petersen; Clifford R Jack; Keith A Josephs
Journal:  Mov Disord       Date:  2016-10-27       Impact factor: 10.338

7.  Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.

Authors:  Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell
Journal:  Ann Neurol       Date:  2020-09-12       Impact factor: 10.422

Review 8.  Tau PET imaging: present and future directions.

Authors:  Laure Saint-Aubert; Laetitia Lemoine; Konstantinos Chiotis; Antoine Leuzy; Elena Rodriguez-Vieitez; Agneta Nordberg
Journal:  Mol Neurodegener       Date:  2017-02-20       Impact factor: 14.195

9.  An autoradiographic evaluation of AV-1451 Tau PET in dementia.

Authors:  Val J Lowe; Geoffry Curran; Ping Fang; Amanda M Liesinger; Keith A Josephs; Joseph E Parisi; Kejal Kantarci; Bradley F Boeve; Mukesh K Pandey; Tyler Bruinsma; David S Knopman; David T Jones; Leonard Petrucelli; Casey N Cook; Neill R Graff-Radford; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Melissa E Murray
Journal:  Acta Neuropathol Commun       Date:  2016-06-13       Impact factor: 7.801

10.  Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation.

Authors:  Christopher G Schwarz; Terry M Therneau; Stephen D Weigand; Jeffrey L Gunter; Val J Lowe; Scott A Przybelski; Matthew L Senjem; Hugo Botha; Prashanthi Vemuri; Kejal Kantarci; Bradley F Boeve; Jennifer L Whitwell; Keith A Josephs; Ronald C Petersen; David S Knopman; Clifford R Jack
Journal:  Neuroimage       Date:  2021-06-09       Impact factor: 6.556

View more
  2 in total

1.  Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies.

Authors:  Arenn F Carlos; Nirubol Tosakulwong; Stephen D Weigand; Marina Buciuc; Farwa Ali; Heather M Clark; Hugo Botha; Rene L Utianski; Mary M Machulda; Christopher G Schwarz; Robert I Reid; Matthew L Senjem; Clifford R Jack; J Eric Ahlskog; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell
Journal:  Brain Commun       Date:  2022-04-28

Review 2.  Clinical Spectrum of Tauopathies.

Authors:  Nahid Olfati; Ali Shoeibi; Irene Litvan
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.